Prices as of 2026/10/30 close
Company comparison
Medipal is the bigger company, with revenue of ¥3.8T — 4.5x Itochu Enex's ¥851.2B.
Itochu Enex earns more on each yen of sales, with an operating margin of 2.8% — 1.4 points above Medipal (1.4%).
Revenue growth in the latest results: Medipal +4.0%, Itochu Enex −7.9%. For next year, Medipal guides for the fastest operating profit growth (+3.4%).
Itochu Enex pays more on average — ¥10.0M against ¥8.14M at Medipal.
Over the past year the shares moved Medipal +37.9%, Itochu Enex +15.4%.
Head-to-head wins14 metrics
One win per metric for the company with the best value. Metrics with no better or worse (P/E, average age, employees) are excluded.
ScaleInvestors
Medipal aheadMedipal 3 : Itochu Enex 0
Revenue: Medipal ¥3.8T / Itochu Enex ¥851.2B
ProfitabilityInvestors
Itochu Enex aheadMedipal 1 : Itochu Enex 2
Operating margin: Medipal 1.4% / Itochu Enex 2.8%
GrowthInvestors
Medipal aheadMedipal 4 : Itochu Enex 0
Revenue growth (YoY): Medipal +4.0% / Itochu Enex −7.9%
Stock & balance sheetInvestors
Medipal aheadMedipal 2 : Itochu Enex 0
Share price, 1 year: Medipal +37.9% / Itochu Enex +15.4%
Pay & workforceJob seekers
EvenMedipal 1 : Itochu Enex 1
Average salary: Medipal ¥8.14M / Itochu Enex ¥10.0M
| Metric | Medipal | Itochu Enex | Gap |
|---|---|---|---|
| Revenue | ◎¥3.8T | ¥851.2B | 4.5x |
| Operating profit | ◎¥53.2B | ¥24.1B | 2.2x |
| Net income | ◎¥42.5B | ¥16.1B | 2.6x |
| Metric | Medipal | Itochu Enex | Gap |
|---|---|---|---|
| Operating margin | 1.4% | ◎2.8% | 1.4pt |
| Net margin | 1.1% | ◎1.9% | 0.8pt |
| Revenue per employee | ◎¥20.6B | ¥2.0B | 10.2x |
| Metric | Medipal | Itochu Enex | Gap |
|---|---|---|---|
| Revenue growth (YoY) | ◎+4.0% | −7.9% | 11.9pt |
| Operating profit growth (YoY) | ◎−4.4% | −10.2% | 5.8pt |
| Revenue CAGRlast 5 years | ◎+3.5% | +2.9% | 0.7pt |
| Guidance: revenue growthnext FY plan | +3.3% | — | |
| Guidance: op. profit growthnext FY plan | ◎+3.4% | +1.5% | 2.0pt |
| Metric | Medipal | Itochu Enex | Gap |
|---|---|---|---|
| Share price, 1 year | ◎+37.9% | +15.4% | 22.5pt |
| Share price, 3 months | ◎+14.6% | +3.4% | 11.2pt |
| Share price (close) | ¥3,441 | ¥2,170 |
◎ marks the best value for each metric. Revenue and profit are from the latest full-year earnings release; share prices are closing-price references; P/E = latest close ÷ trailing EPS. For banks and some other financials, revenue means ordinary income.
| Metric | Medipal | Itochu Enex | Gap |
|---|---|---|---|
| Average salary | ¥8.14M | ◎¥10.0M | ¥1.87M |
| Starting salary (monthly) | — | ¥300,000 | |
| Average tenure | ◎19.8 yrs | 15.7 yrs | 4.1 |
| Average age | 48.6 | 41.3 | 7.3 |
| Employees | 185 | 421 | 2.3x |
Average salary is for the reporting (parent) company and is affected by average age and job mix. Holding companies with few employees are left out of the salary comparison.
Close (Oct 30, 2026)
¥3,441+37.9% (1Y)
Medipal +37.9% over 1Y. Compared: Itochu Enex +15.4%.
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Each line shows the % change from the start of the period. Updated Oct 30, 2026.
Medipal3 segments
Itochu Enex4 segments
AAverage annual salary from the securities filings: Itochu Enex ¥10.0M, Medipal ¥8.14M. Itochu Enex pays the most. Averages also depend on staff age and job mix, so check the average age too (Medipal 48.6, Itochu Enex 41.3).
ARevenue in the latest results: Medipal ¥3.8T, Itochu Enex ¥851.2B. Medipal is the bigger company, with revenue of ¥3.8T — 4.5x Itochu Enex's ¥851.2B.
AOperating margins: Itochu Enex 2.8%, Medipal 1.4%. Itochu Enex turns the highest share of sales into operating profit.
AShare price change over the past year (closing prices, for reference): Medipal +37.9%, Itochu Enex +15.4%. Medipal has risen the most.
Comparing 2 companies (up to 4)
Sources: earnings releases (kessan tanshin), annual securities reports and other public information. Share prices are closing-price references, not real-time. Our data may contain errors; investment decisions are your own responsibility.
